4(R)-1-benzyl-4-[9-((1R,2S,3R,5R)-1,2-dihydroxy-5-hydroxymethylcyclopent-3-yl)-9H-purin-6-ylamino]pyrrolidin-2-one hydrochloride | 202267-52-5

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 核苷和核苷酸类似物
• 英文名称: 4(R)-1-benzyl-4-[9-((1R,2S,3R,5R)-1,2-dihydroxy-5-hydroxymethylcyclopent-3-yl)-9H-purin-6-ylamino]pyrrolidin-2-one hydrochloride
• 英文别名: (4R)-1-benzyl-4-[[9-[(1R,2S,3R,4R)-2,3-dihydroxy-4-(hydroxymethyl)cyclopentyl]purin-6-yl]amino]pyrrolidin-2-one;hydrochloride
• CAS: 202267-52-5
• 化学式: C₂₂H₂₆N₆O₄*ClH
• 分子量: 474.947
• InChiKey: KTKDKUFUQJDERV-JCGFXKOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.74
• 重原子数：
  33
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  137
• 氢给体数：
  5
• 氢受体数：
  8

文献信息

• Methods of treating insulin resistance syndrome and diabetes
  申请人：——

  公开号：US20030176390A1

  公开（公告）日：2003-09-18

  This invention is directed to methods of treating insulin resistance syndrome and diabetes in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a compound derived from adenosine and analogues thereof, or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable prodrug thereof, an N-oxide thereof, a hydrate thereof or a solvate thereof, or a pharmaceutical composition comprising such compound.

  本发明涉及治疗胰岛素抵抗综合征和糖尿病的方法，包括向需要治疗的患者施用从腺苷和其类似物衍生的化合物的药效量，或其药用盐、药用前药、N-氧化物、水合物或溶剂化合物，或包含该化合物的药物组合物。
• COMPOUNDS HAVING ANTIHYPERTENSIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC AND ANTILIPOLYTIC PROPERTIES
  申请人：Aventis Pharmaceuticals Products Inc.

  公开号：EP0912520B1

  公开（公告）日：2003-05-07